Using ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) liquid biopsy has been revealed to result in a 30-fold increase in tumour cells harvested for analysis in cancer patients.
Parsortix was deployed by a Düsseldorf team called Disseminated Cancer Cell Network.
The researchers and clinicians were attempting to enhance a technique called diagnostic leukapheresis, which harvests circulating tumour cells (CTCSs) to assess how to better treat patients individually.
The increase in the number of CTCs captured by Parsortix was highly effective in reducing the “background” produced by white blood cells caught during the process.
“The Parsortix system provides an easy solution for enriching the sample and harvesting these CTCs keeping the cells alive and undamaged,” said researcher Dr Hans Neubauer.
“The workflow we have developed to culture these cells will allow an intensification of research into new diagnostic and therapeutic solutions."
The results from the work carried out by the Disseminated Cancer Cell Network were peer-reviewed
and published in the periodical Clinical Chemistry. Click here to read.